EpiCast Report: Diabetic Retinopathy - Epidemiology Forecast to 2022

Summary

Diabetic retinopathy is the principal cause of vision impairment in working-age adults throughout the world. A common microvascular complication of diabetes, diabetic retinopathy affects a third of diagnosed diabetics (Cheung et al., 2010). Clinically defined as an eye disease damaging the small blood vessels in the retina, diabetic retinopathy results from chronically high blood glucose levels in people with poorly-managed diabetes (Cheung et al., 2010; Fong et al., 2004; Kawasaki et al., 2011; Rubino et al., 2007).


According to the epidemiological literature, the duration of diabetes, hyperglycemia, hypertension, and dyslipidemia are all risk factors for the disease. Additionally, diabetic retinopathy has a comorbid relationship with various cardiovascular diseases. However, the causal pathway of this relationship has yet to be determined (Fong et al., 2004; Kawasaki et al., 2011; Klein et al., 2002).


According to GlobalData’s forecast, the 7MM had 4,889,171 prevalent cases of diabetic retinopathy in 2012. The prevalent cases in the 7MM are expected to increase to 7,176,537 cases by 2022, at an Annual Growth Rate (AGR) of 4.68%. Japan had the largest proportion of prevalent cases in 2012 (61.21%, or 2,992,840 cases) of all the markets covered in this analysis.

Scope

- The diabetic retinopathy EpiCast Report provides an overview of the risk factors and epidemiological trends for diabetic reitnopathy in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of diabetic retinopathy in the diagnosed diabetic population segmented by age, (over 40 years of age) and sex. The diagnosed prevalent cases are then further segmented by the grade of diabetic retinopathy (vision-threatening diabetic retinopathy [VTDR] and diabetic macular edema [DME]).
- The diabetic retinopathy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global diabetic retinopathy market.
- Quantify patient populations in the global diabetic retinopathy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for diabetic retinopathy therapeutics in each of the markets covered.

Table Of Contents

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 12
3.3.1 US 13
3.3.2 5EU 14
3.3.3 Japan 16
3.4 Epidemiological Forecast for Diabetic Retinopathy (2012-2022) 17
3.4.1 Forecast Methodology 17
3.4.2 Sources Used 19
3.4.3 Sources Not Used 22
3.4.4 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 23
3.4.5 Forecast Assumptions and Methods — Diabetic Retinopathy 27
3.5 Epidemiology Forecast for Diabetic Retinopathy (2012-2022) 29
3.5.1 Diagnosed Prevalent Cases of Diabetic Retinopathy 29
3.5.2 Diagnosed Prevalent Cases of Diabetic Retinopathy by Age 31
3.5.3 Diagnosed Prevalent Cases of Diabetic Retinopathy by Sex 33
3.5.4 Diagnosed Prevalent Cases of Diabetic Retinopathy, Severity Grades in the 5EU 35
3.6 Discussion 37
3.6.1 Conclusions on Epidemiological Trends 37
3.6.2 Limitations of the Analysis 38
3.6.3 Strengths of the Analysis 39
4 Appendix 40
4.1 Bibliography 40
4.2 About the Authors 45
4.2.1 Epidemiologists 45
4.2.2 Reviewers 45
4.2.3 Global Director of Epidemiology and Health Policy 46
4.2.4 Global Head of Healthcare 47
4.3 About GlobalData 48
4.4 About EpiCast 48
4.5 Disclaimer 49



List of Tables

Table 1: International Clinical Diabetic Retinopathy Disease Severity Scale and ETDRS Severity 10
Table 2: Summary of the Reported Prevalence Rates of Diabetic Retinopathy Across the 5EU 15
Table 3: 7MM, Sources for Diagnosed Diabetic Retinopathy Prevalence 17
Table 4: 7MM, Prevalent Cases of Diabetic Retinopathy in the Diagnosed Diabetic Population, N (%), Select Years, 2012-2022 30
Table 5: 7MM, Age-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy in the Diagnosed Diabetic Population, N (Row %), 2012 31
Table 6: 7MM, Sex-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy in the Diagnosed Diabetic Population, N (Row %), 2012 33



List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of Diabetic Retinopathy in the Diagnosed Diabetic Population, Both Sexes, Ages ? 40 Years, N, 2012-2022 30
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy in the Diagnosed Diabetic Population, N, 2012-2022 32
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Diabetic Retinopathy in the Diagnosed Diabetic Population, N , 2012 34
Figure 4: 5EU, Age-Specific Diagnosed Prevalent Cases of VTDR in the Diagnosed Diabetic Population, N, 2012 36
Figure 5: 4EU, Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Population, N, 2012 36

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Blood-Brain Barrier Technologies and Global Markets

Blood-Brain Barrier Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research report analyzes the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential, determines its current market status, examines ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.